Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma
Anticancer Research · 2025
DOI: 10.21873/anticanres.17889 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2025. Verfasst von Takehiro Nakao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Ovarian Epithelial, Tertiary Lymphoid Structures, Ovarian Neoplasms.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; kharano@east.ncc.go.jp.
- Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan.
- Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Japan.
- Department of Gynecology, National Cancer Center Hospital East, Kashiwa, Japan.
Zitieren
APA
Nakao, T., Harano, K., Wakabayashi, M., Taki, T., Watanabe, R., Tanabe, H., & Mukohara, T. (2025). Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma. Anticancer Research. https://doi.org/10.21873/anticanres.17889
Vancouver
Nakao T, Harano K, Wakabayashi M, Taki T, Watanabe R, Tanabe H, et al. Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma. Anticancer Research. 2025. doi:10.21873/anticanres.17889
BibTeX
@article{Nakao2025,
author = {Nakao, Takehiro and Harano, Kenichi and Wakabayashi, Masashi and Taki, Tetsuro and Watanabe, Reiko and Tanabe, Hiroshi and Mukohara, Toru},
title = {Prognostic Value of Tertiary Lymphoid Structures in Epithelial Ovarian Carcinoma},
journal = {Anticancer Research},
year = {2025},
doi = {10.21873/anticanres.17889}
}
EUVIMED